{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:27:32Z","timestamp":1792794452573,"version":"4.5.0"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"Supplement_6","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Arthritis Experimental Osteoarthritis Treatment Centre","award":["20800"],"award-info":[{"award-number":["20800"]}],"id":[{"id":"https:\/\/ror.org\/043gt9j70","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"crossref","award":["EP\/P001076\/1"],"award-info":[{"award-number":["EP\/P001076\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>OA is an increasingly common, painful condition with complex aetiology and limited therapies. Approaches to expanding our therapeutic armamentarium have included repurposing existing therapies used for other rheumatological conditions, modifying existing OA preparations to enhance their benefits, and identifying new therapeutics. HCQ and low-dose MTX have been unsuccessful in improving hand OA pain or reducing structural progression. Anti-IL-6 and anti-GM-CSF also did not improve symptoms in hand OA trials, but IL-1 remains an intriguing target for large-joint OA, based on reduced joint replacements in a post hoc analysis from a large cardiovascular disease trial. The peripheral nociceptive pathway appears an attractive target, with mAbs to nerve growth factor and IA capsaicin demonstrating efficacy; tropomyosin receptor kinase A inhibitors are at an earlier stage of development. Limited evidence suggests pharmacological therapies can modify cartilage and bone structural progression, though evidence of synchronous symptom benefits are lacking.<\/jats:p>","DOI":"10.1093\/rheumatology\/keab679","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T23:08:04Z","timestamp":1631142484000},"page":"vi1-vi11","source":"Crossref","is-referenced-by-count":23,"title":["New developments in osteoarthritis pharmacological therapies"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2514-5022","authenticated-orcid":false,"given":"Asim","family":"Ghouri","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2418-2104","authenticated-orcid":false,"given":"Jonathan G.","family":"Quicke","sequence":"additional","affiliation":[{"name":"Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, Staffordshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Conaghan","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"2021122420120757100_keab679-B1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"2021122420120757100_keab679-B2","doi-asserted-by":"crossref","first-page":"16072","DOI":"10.1038\/nrdp.2016.72","article-title":"Osteoarthritis","volume":"2","author":"Martel-Pelletier","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2021122420120757100_keab679-B3","doi-asserted-by":"crossref","first-page":"iv43","DOI":"10.1093\/rheumatology\/kex419","article-title":"Osteoarthritis: the genesis of pain","volume":"57","author":"Fu","year":"2018","journal-title":"Rheumatology"},{"key":"2021122420120757100_keab679-B4","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","article-title":"OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis","volume":"27","author":"Bannuru","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B5","doi-asserted-by":"crossref","first-page":"1735242","DOI":"10.1155\/2019\/1735242","article-title":"Minimally manipulated mesenchymal stem cells for the treatment of knee osteoarthritis: a systematic review of clinical evidence","volume":"2019","author":"Di Matteo","year":"2019","journal-title":"Stem Cells Int"},{"key":"2021122420120757100_keab679-B6","doi-asserted-by":"crossref","first-page":"232596711989790","DOI":"10.1177\/2325967119897909","article-title":"Hyaluronic acid injections or oral nonsteroidal anti-inflammatory drugs for knee osteoarthritis: systematic review and meta-analysis of randomized trials","volume":"8","author":"Miller","year":"2020","journal-title":"Orthopaedic J Sports Med"},{"key":"2021122420120757100_keab679-B7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10067-020-05185-2","article-title":"The effects of platelet-rich plasma injection in knee and hip osteoarthritis: a meta-analysis of randomized controlled trials","volume":"40","author":"Dong","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2021122420120757100_keab679-B8","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s40265-020-01423-8","article-title":"Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: a systematic review and a network meta-analysis with a 6-month time horizon","volume":"80","author":"Beaudart","year":"2020","journal-title":"Drugs"},{"key":"2021122420120757100_keab679-B9","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(19)32489-4","article-title":"Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial","volume":"394","author":"Kroon","year":"2019","journal-title":"Lancet"},{"key":"2021122420120757100_keab679-B10","first-page":"2757","article-title":"Clinical Effectiveness of Ultrasound-guided Intra-articular Corticosteroid and Local Anaesthetic Injections for Hip Osteoarthritis: a randomised controlled trial (HIT) [abstract]","volume":"71(suppl 10","author":"Paskins","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/annrheumdis-2020-eular.819","article-title":"OP0186 Hydroxychloroquine in Patients with Inflammatory and Erosive Osteoarthritis of the Hands: results of a randomized, double-blind, placebo controlled, multi-centre, investigator-initiated trial (OA treat)","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021122420120757100_keab679-B12","first-page":"1759","article-title":"Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: a randomized, double-blind, placebo-controlled trial [abstract]","volume":"71 (suppl 10","author":"Ferrero","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B13","first-page":"428","article-title":"Significant Pain Reduction with Oral Methotrexate in Knee Osteoarthritis; results from a randomised controlled phase III trial of treatment effectiveness [abstract]","volume":"70 (suppl 10","author":"Kingsbury","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2020-218547","article-title":"Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial","volume":"80","author":"Richette","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2021122420120757100_keab679-B15","doi-asserted-by":"crossref","first-page":"797.1","DOI":"10.1136\/annrheumdis-2020-eular.4040","article-title":"FRI0399 Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH)","volume":"79","author":"Davis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021122420120757100_keab679-B16","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.2020.2938","article-title":"Effect of intravenous zoledronic acid on tibiofemoral cartilage volume among patients with knee osteoarthritis with bone marrow lesions: a randomized clinical trial","volume":"323","author":"Cai","year":"2020","journal-title":"JAMA"},{"key":"2021122420120757100_keab679-B17","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.semarthrit.2020.09.007","article-title":"A novel diclofenac gel (AMZ001) applied once or twice daily in subjects with painful knee osteoarthritis: a randomized, placebo-controlled clinical trial","volume":"50","author":"Bihlet","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2021122420120757100_keab679-B18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jos.2020.04.014","article-title":"Effect and usability of anti-inflammatory drug plasters for knee osteoarthritis: a crossover, double-blind, repeated measures, randomized controlled trial","volume":"26","author":"Tanabe","year":"2021","journal-title":"J Orthopaed Sci"},{"key":"2021122420120757100_keab679-B19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.arth.2020.08.036","article-title":"Intra-articular injections of the hip and knee with triamcinolone vs ketorolac: a randomized controlled trial","volume":"36","author":"Jurgensmeier","year":"2021","journal-title":"J Arthroplasty"},{"key":"2021122420120757100_keab679-B20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2106\/JBJS.17.00154","article-title":"Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study","volume":"100","author":"Conaghan","year":"2018","journal-title":"JBJS"},{"key":"2021122420120757100_keab679-B21","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.joca.2019.02.124","article-title":"Single intra-articular injection of TLC599 provided sustained pain relief through 24 weeks in participants with symptomatic knee osteoarthritis","volume":"27","author":"Hunter","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/annrheumdis-2019-216296","article-title":"Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period","volume":"79","author":"Berenbaum","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021122420120757100_keab679-B23","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/art.41012","article-title":"The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase IIb\/III double-blind, placebo-controlled, randomized clinical trial","volume":"71","author":"Dakin","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B24","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.joca.2019.05.028","article-title":"Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study","volume":"27","author":"Krupka","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B25","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.joca.2019.05.029","article-title":"Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial","volume":"27","author":"Watt","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jcph.1470","article-title":"Efficacy, safety, and tolerability of ONO-4474, an orally available pan-tropomyosin receptor kinase inhibitor, in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, placebo-controlled, double-blind, parallel-group comparative study","volume":"60","author":"Ishiguro","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2021122420120757100_keab679-B27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/annrheumdis-2020-eular.2200","article-title":"OP0187 determining optimal cooling and administration methods for CNTX-4975 intra-articular injection in subjects with moderate to severe osteoarthritis knee pain","volume":"79","author":"Stevens","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021122420120757100_keab679-B28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.joca.2019.09.002","article-title":"Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"28","author":"Rovati","year":"2020","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B29","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/art.40840","article-title":"A phase II trial of lutikizumab, an anti\u2013interleukin-1\u03b1\/\u03b2 dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/annrheumdis-2018-213336","article-title":"Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1\u03b1 and anti-interleukin-1\u03b2 dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis","volume":"78","author":"Kloppenburg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021122420120757100_keab679-B31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7326\/M20-0527","article-title":"Effects of interleukin-1\u03b2 inhibition on incident hip and knee replacement: exploratory analyses from a randomized, double-blind, placebo-controlled trial","volume":"173","author":"Schieker","year":"2020","journal-title":"Ann Intern Med"},{"key":"2021122420120757100_keab679-B32","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1016\/S2665-9913(20)30171-5","article-title":"Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial","volume":"2","author":"Schett","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2021122420120757100_keab679-B33","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2019.14735","article-title":"Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial","volume":"322","author":"Hochberg","year":"2019","journal-title":"JAMA"},{"key":"2021122420120757100_keab679-B34","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1016\/j.joca.2018.02.502","article-title":"TPX-100 leads to marked, sustained improvements in subjects with knee osteoarthritis: pre-clinical rationale and results of a controlled clinical trial","volume":"26","author":"McGuire","year":"2018","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/M19-0675","article-title":"Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis: a randomized, placebo-controlled study","volume":"172","author":"Conaghan","year":"2020","journal-title":"Ann Intern Med"},{"key":"2021122420120757100_keab679-B36","first-page":"519","article-title":"THU0458 Efficacy and safety from a phase 2B trial of SM04690, a novel intra-articular Wnt pathway inhibitor for the treatment of osteoarthritis of the knee","volume":"78","author":"Yazici","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021122420120757100_keab679-B37","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/acr.23471","article-title":"Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebo-controlled trial","volume":"70","author":"Lee","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2021122420120757100_keab679-B38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.7326\/M17-1430","article-title":"Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial","volume":"168","author":"Kingsbury","year":"2018","journal-title":"Ann Intern Med"},{"key":"2021122420120757100_keab679-B39","doi-asserted-by":"crossref","first-page":"e001660","DOI":"10.1136\/rmdopen-2021-001660","article-title":"Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study\u2014a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"7","author":"Kedor","year":"2021","journal-title":"RMD Open"},{"key":"2021122420120757100_keab679-B40","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/rheumatology\/keaa248","article-title":"A roadmap to target interleukin-6 in osteoarthritis","volume":"59","author":"Wiegertjes","year":"2020","journal-title":"Rheumatology"},{"key":"2021122420120757100_keab679-B41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/acr.20373","article-title":"Pain sensitivity and pain reactivity in osteoarthritis","volume":"63","author":"Lee","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021122420120757100_keab679-B42","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41584-018-0078-5","article-title":"Calcium crystal deposition diseases \u2013 beyond gout","volume":"14","author":"McCarthy","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2021122420120757100_keab679-B43","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.joca.2018.01.026","article-title":"Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial","volume":"26","author":"Leung","year":"2018","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-015-0735-x","article-title":"A systematic review of the relationship between subchondral bone features, pain and structural pathology in peripheral joint osteoarthritis","volume":"17","author":"Barr","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2021122420120757100_keab679-B45","doi-asserted-by":"crossref","first-page":"100664","DOI":"10.1016\/j.conctc.2020.100664","article-title":"Evaluation of efficacy and safety of a novel lipogel containing diclofenac: a randomized, placebo controlled, double-blind clinical trial in patients with signs and symptoms of osteoarthritis","volume":"20","author":"Bhatia","year":"2020","journal-title":"Contempor Clin Trials Commun"},{"key":"2021122420120757100_keab679-B46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/art.40364","article-title":"Brief report: a phase IIb trial of a novel extended-release microsphere formulation of triamcinolone acetonide for intraarticular injection in knee osteoarthritis","volume":"70","author":"Conaghan","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B47","doi-asserted-by":"crossref","first-page":"1759720x19881309","DOI":"10.1177\/1759720X19881309","article-title":"A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritis","volume":"11","author":"Kivitz","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2021122420120757100_keab679-B48","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.2017.5283","article-title":"Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial","volume":"317","author":"McAlindon","year":"2017","journal-title":"JAMA"},{"key":"2021122420120757100_keab679-B49","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1148\/radiol.2019190341","article-title":"Intra-articular corticosteroid injections in the hip and knee: perhaps not as safe as we thought?","volume":"293","author":"Kompel","year":"2019","journal-title":"Radiology"},{"key":"2021122420120757100_keab679-B50","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1148\/radiol.2020200771","article-title":"Intra-articular corticosteroid injections for the treatment of hip and knee osteoarthritis-related pain: considerations and controversies with a focus on imaging\u2014Radiology scientific expert panel","volume":"297","author":"Guermazi","year":"2020","journal-title":"Radiology"},{"key":"2021122420120757100_keab679-B51","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00167-017-4470-5","article-title":"Single-dose local anesthetics exhibit a type-, dose-, and time-dependent chondrotoxic effect on chondrocytes and cartilage: a systematic review of the current literature","volume":"26","author":"Kreuz","year":"2018","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"2021122420120757100_keab679-B52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/ALN.0b013e31821b1ac5","article-title":"Antagonism of nerve growth factor-TrkA signaling and the relief of pain","volume":"115","author":"Mantyh","year":"2011","journal-title":"Anesthesiology"},{"key":"2021122420120757100_keab679-B53","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrrheum.2013.138","article-title":"Towards a mechanism-based approach to pain management in osteoarthritis","volume":"9","author":"Malfait","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"2021122420120757100_keab679-B54","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1110\/ps.035402.108","article-title":"Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors","volume":"17","author":"Abdiche","year":"2008","journal-title":"Protein Sci"},{"key":"2021122420120757100_keab679-B55","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/JPR.S191297","article-title":"Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip","volume":"12","author":"Tive","year":"2019","journal-title":"J Pain Res"},{"key":"2021122420120757100_keab679-B56","first-page":"374","article-title":"Efficacy and safety of tanezumab on osteoarthritis knee and hip pains: a meta-analysis of randomized controlled trials","volume":"18","author":"Chen","year":"2017","journal-title":"Pain Med"},{"key":"2021122420120757100_keab679-B57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2019.8044","article-title":"Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial","volume":"322","author":"Schnitzer","year":"2019","journal-title":"JAMA"},{"key":"2021122420120757100_keab679-B58","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.pain.2013.04.035","article-title":"A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee","volume":"154","author":"Spierings","year":"2013","journal-title":"PAIN"},{"key":"2021122420120757100_keab679-B59","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/annrheumdis-2013-204905","article-title":"Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain","volume":"74","author":"Schnitzer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021122420120757100_keab679-B60","first-page":"1302","article-title":"Subcutaneous tanezumab vs NSAID for the treatment of osteoarthritis: efficacy and general safety results from a randomized, double-blind, active-controlled, 80-week, phase-3 study [abstract]","volume":"71","author":"Hochberg","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B61","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.joca.2014.10.005","article-title":"Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies","volume":"23(suppl 1","author":"Hochberg","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B62","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.39492","article-title":"When is osteonecrosis not osteonecrosis? adjudication of reported serious adverse joint events in the tanezumab clinical development program","volume":"68","author":"Hochberg","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B63","doi-asserted-by":"crossref","first-page":"iv99","DOI":"10.1093\/rheumatology\/kex522","article-title":"What is new in pain modification in osteoarthritis?","volume":"57","author":"Miller","year":"2018","journal-title":"Rheumatology"},{"key":"2021122420120757100_keab679-B64","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/art.41674","article-title":"Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial","volume":"73","author":"Hochberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B65","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.joca.2019.07.013","article-title":"A tale of two TrkA inhibitor trials: same target, divergent results. Osteoarthritis and cartilage\/OARS","volume":"27","author":"Walsh","year":"2019","journal-title":"Osteoarthritis Res Soc"},{"key":"2021122420120757100_keab679-B66","year":"2018"},{"key":"2021122420120757100_keab679-B67","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrd2280","article-title":"The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept","volume":"6","author":"Szallasi","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"2021122420120757100_keab679-B68","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/bmj.38042.506748.EE","article-title":"Systematic review of topical capsaicin for the treatment of chronic pain","volume":"328","author":"Mason","year":"2004","journal-title":"BMJ"},{"key":"2021122420120757100_keab679-B69","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/art.40894","article-title":"Randomized, double-blind, placebo-controlled trial of intra-articular CNTX-4975 (trans-capsaicin) for pain associated with osteoarthritis of the knee","volume":"71","author":"Stevens","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B70","author":"Stevens","year":"2018"},{"key":"2021122420120757100_keab679-B71","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/j.joca.2020.02.228","article-title":"Preliminary results from a phase 1b double-blind study to assess the safety, tolerability and efficacy of intra-articular administration of resiniferatoxin or placebo for the treatment of moderate to severe pain due to osteoarthritis of the knee","volume":"28","author":"Leiman","year":"2020","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B72","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.18831.1","article-title":"IL-1 in osteoarthritis: time for a critical review of the literature","volume":"8","author":"Vincent","year":"2019","journal-title":"F1000Res"},{"key":"2021122420120757100_keab679-B73","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/art.24096","article-title":"Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study","volume":"61","author":"Chevalier","year":"2009","journal-title":"Arthritis Care Res"},{"key":"2021122420120757100_keab679-B74","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/19420862.2015.1026501","article-title":"Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-IgTM) molecule that specifically and potently neutralizes both IL-1\u03b1 and IL-1\u03b2","volume":"7","author":"Lacy","year":"2015","journal-title":"MAbs"},{"key":"2021122420120757100_keab679-B75","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"New Engl J Med"},{"key":"2021122420120757100_keab679-B76","doi-asserted-by":"crossref","first-page":"R199","DOI":"10.1186\/ar4037","article-title":"Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development","volume":"14","author":"Cook","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2021122420120757100_keab679-B77","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1097\/PR9.0000000000000676","article-title":"Granulocyte-macrophage colony-stimulating factor receptor expression in clinical pain disorder tissues and role in neuronal sensitization","volume":"3","author":"Donatien","year":"2018","journal-title":"Pain Rep"},{"key":"2021122420120757100_keab679-B78","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.joca.2005.03.003","article-title":"Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis","volume":"13","author":"Moore","year":"2005","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B79","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.38614","article-title":"Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial","volume":"66","author":"Lohmander","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B80","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.joca.2020.08.005","article-title":"Automated MRI assessment confirms cartilage thickness modification in patients with knee osteoarthritis: post-hoc analysis from a phase II sprifermin study","volume":"28","author":"Brett","year":"2020","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B81","first-page":"1486","article-title":"Long-term efficacy and safety of intra-articular sprifermin in patients with knee osteoarthritis: results from the 5-year forward study [abstract]","volume":"72","author":"Eckstein","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B82","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.semarthrit.2021.03.005","article-title":"The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial","volume":"51","author":"Guehring","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2021122420120757100_keab679-B83","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12967-018-1497-4","article-title":"Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711","volume":"16","author":"Lindstr\u00f6m","year":"2018","journal-title":"J Transl Med"},{"key":"2021122420120757100_keab679-B84","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S2213-8587(19)30346-8","article-title":"Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study","volume":"7","author":"McClung","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2021122420120757100_keab679-B85","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.joca.2017.08.015","article-title":"A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee","volume":"26","author":"Deshmukh","year":"2018","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B86","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11926-017-0679-z","article-title":"Wnt\/\u03b2-catenin signaling in osteoarthritis and in other forms of arthritis","volume":"19","author":"Zhou","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"2021122420120757100_keab679-B87","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.joca.2019.05.006","article-title":"Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment","volume":"27","author":"Deshmukh","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"key":"2021122420120757100_keab679-B88","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/art.41315","article-title":"Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: a phase II Randomized trial","volume":"72","author":"Yazici","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B89","first-page":"1308","article-title":"Subject enrichment criteria for phase 3 studies of lorecivivint (SM04690), a potential disease-modifying knee osteoarthritis drug: a post hoc study on the effects of baseline comorbid pain and joint space width on patient-reported outcomes [abstract]","volume":"71","author":"Kennedy","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120757100_keab679-B90","author":"Yazici"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/Supplement_6\/vi1\/41928832\/keab679.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/Supplement_6\/vi1\/41928832\/keab679.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T22:17:46Z","timestamp":1725747466000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/Supplement_6\/vi1\/6482885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":90,"journal-issue":{"issue":"Supplement_6","published-online":{"date-parts":[[2021,12,24]]},"published-print":{"date-parts":[[2021,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab679","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,11,1]]}}}